Carcinoma Clinical Trial
Official title:
Prospective Study to Assess the Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Patients With Carcinoma of the Upper Aerodigestive Tract
Hypothesis
1. The submandibular gland is not a lymphatic organ and usually remains uninvolved with
head and neck cancer despite the presence of metastatic disease in the lymph nodes that
surround it.
2. All the lymph nodes in the submandibular triangle can be removed without resection of
the submandibular gland.
Study Design
A better understanding of the frequency of submandibular gland involvement may lead to
refined treatment strategies for head and neck cancer, which can possibly spare removal of
the submandibular gland and potentially improve the long term side effects from therapy.
Hypothesis
1. The submandibular gland is not a lymphatic organ and usually remains uninvolved with
head and neck cancer despite the presence of metastatic disease in the lymph nodes that
surround it.
2. All the lymph nodes in the submandibular triangle can be removed without resection of
the submandibular gland.
Study Design
1. A prospective controlled study.
2. A neck dissection of at least the ipsilateral sub-level 1B will be performed in all
patients. In case of oral cavity tumors, about 15 minutes prior to the surgery, 1ml of
Lymphazurin® blue dye will be injected in 4 quadrants around the primary site. The
dissection will be performed in 3 stages. In the first stage all lymph node groups that
lie either lateral, anterior, posterior, superior, or inferior to the submandibular
gland, but within anatomical boundaries of level 1B, will be dissected. The
submandibular gland will be left intact for this portion of the procedure. Next, the
submandibular gland will be removed. Lastly, any remaining fibrofatty tissue that lies
deep to the submandibular gland within the confines of level IB will be removed. Each
lymph node group, the submandibular gland, and the fibrofatty tissue lying deep to the
submandibular gland, will be submitted for pathological assessment in separate
containers.
3. The following end-points will be measured: the number of lymph nodes identified within
each lymph node group, the number of lymph nodes located within the submandibular
gland, and the number of lymph nodes within the fibrofatty contents lying deep to the
submandibular gland. The presence or absence of carcinoma within each of the assessed
nodes will be documented, as well as extracapsular spread.
A better understanding of the frequency of submandibular gland involvement may lead to
refined treatment strategies for head and neck cancer, which can possibly spare removal of
the submandibular gland and potentially improve the long term side effects from therapy.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05283226 -
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT04362072 -
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
|
Phase 4 | |
| Completed |
NCT04033991 -
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
|
||
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
| Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT01942200 -
A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer
|
||
| Completed |
NCT01061645 -
Study of MOC31-PE in Antigen Positive Carcinomas
|
Phase 1 | |
| Terminated |
NCT00557596 -
A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00532155 -
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT00216372 -
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
|
Phase 3 | |
| Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05520281 -
Short-term Psychodynamic Psychotherapy in Serious Physical Illness
|
N/A | |
| Recruiting |
NCT05752357 -
The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.
|
||
| Not yet recruiting |
NCT05023928 -
Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer
|
Phase 1 | |
| Completed |
NCT00446446 -
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
|
Phase 2 | |
| Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06112041 -
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
|
Phase 2 | |
| Completed |
NCT03562897 -
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
|
Phase 2 | |
| Recruiting |
NCT06013111 -
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
|
Phase 1 |